Does thalassemia increase the risk of bleeding?

Thalassemia and Bleeding Risk: A Paradoxical Hemostatic Profile

Thalassemia does NOT increase bleeding risk in the traditional sense; rather, it creates a complex hemostatic imbalance where patients paradoxically have BOTH bleeding tendencies AND thrombotic risk, with the thrombotic risk being the dominant clinical concern, particularly in thalassemia intermedia and after splenectomy.

Understanding the Hemostatic Paradox

The hemostatic system in thalassemia patients exists in a precarious balance. While laboratory abnormalities suggest bleeding potential, the clinical reality is more nuanced:

Laboratory Evidence of "Bleeding Tendency"

Multiple studies demonstrate coagulation abnormalities that theoretically favor bleeding 1, 2, 3:

• Prolonged PT and aPTT are common (40.7% and 46.3% respectively in one cohort) 2
• Platelet dysfunction is consistently observed, with decreased aggregation to ADP (64%), ristocetin (68%), arachidonic acid (64%), and epinephrine (48%) 4, 3
• Reduced natural anticoagulants: Protein C deficiency (26.2%), Protein S deficiency (28.6%), and Antithrombin III deficiency (46.8%) 2

Clinical Bleeding Manifestations

When bleeding occurs, it typically presents as:

• Mucosal bleeding (96% of symptomatic patients) 4
• Easy bruising and frequent epistaxis 3
• Increased postpartum hemorrhage risk (RR = 2.40) in pregnant women with thalassemia minor 5

However, these bleeding episodes correlate with age, liver size, and number of transfusions—NOT with the severity of coagulation abnormalities 2.

The Dominant Clinical Reality: Thrombotic Risk

The critical clinical point is that thalassemia, particularly thalassemia intermedia, carries a GREATER propensity for thrombosis than bleeding 6. According to the American Heart Association consensus statement:

• Thalassemia intermedia has a "greater propensity to pulmonary hypertension and thrombosis" 6
• This thrombotic tendency is disease-specific and related to:
  • Reactive oxygen species
  • Pathological erythroid cells
  • Circulating microparticles
  • Free heme
  • Endothelial activation 7

Splenectomy: The Game-Changer

Splenectomy dramatically shifts the balance toward thrombosis 8:

• Platelet count increases by 45.2%
• PAI-1 (plasminogen activator inhibitor-1) increases by 98.1%
• Fibrinogen increases by 18.9%
• tPA increases by 197.2%

A strong positive correlation exists between platelet count and PAI-1 (r = 0.669) in thalassemia patients 8.

Clinical Decision-Making Algorithm

For Beta-Thalassemia Major (Transfusion-Dependent)

1. Baseline state: Deranged hemostatic parameters exist from early childhood, but a state of balance prevents clinical events 1

2. Monitor for imbalance triggers:

   • Iron overload (serum ferritin correlates with PT prolongation and low Protein S) 2
   • Hepatic dysfunction from iron deposition
   • Splenectomy status
   • Medication effects (deferiprone associated with deficient ristocetin/collagen response) 4

3. If bleeding occurs: Consider platelet function defects, especially if:

   • Frequent transfusions (negatively correlates with aggregation) 4
   • On deferiprone chelation 4
   • On hydroxyurea (impairs ristocetin response) 4

For Thalassemia Intermedia (Non-Transfusion-Dependent)

Thrombotic risk is the PRIMARY concern 6:

• Prophylaxis for thromboembolism with heparin or low-molecular-weight heparin is indicated, particularly in splenectomized patients 6
• Monitor for pulmonary hypertension
• Consider anticoagulation in high-risk scenarios (pregnancy, post-splenectomy, atrial fibrillation)

Critical Pitfalls to Avoid

1. Do NOT assume bleeding risk based solely on laboratory abnormalities: Despite prolonged PT/aPTT and platelet dysfunction, many patients never experience significant bleeding 1, 2

2. Do NOT overlook thrombotic risk: The hemostatic balance can tip toward thrombosis, especially with:

   • Splenectomy
   • Advancing age
   • Atrial fibrillation (emerging complication with increased survival) 7
   • New medications like luspatercept (role in thrombotic risk still being elucidated) 7

3. Pregnancy considerations: In pregnant women with thalassemia, prophylaxis for thromboembolism is indicated, particularly in splenectomized patients and those with thalassemia intermedia 6, despite the increased postpartum hemorrhage risk 5

The Bottom Line

Despite laboratory evidence of coagulation abnormalities and occasional bleeding manifestations, thalassemia patients—particularly those with thalassemia intermedia or post-splenectomy—are at GREATER risk for thrombosis than clinically significant bleeding. The hemostatic system exists in a delicate balance that can be disrupted by iron overload, splenectomy, medications, and age 1, 2. Clinical management should prioritize thrombotic risk assessment and prophylaxis in high-risk scenarios, while recognizing that platelet dysfunction may contribute to bleeding in specific contexts (frequent transfusions, certain chelators, surgical procedures).